

Analytical Test Report

Science First. ORELAP ID: 4101 OLCC#: 010-10233216933
20756 High Desert Court STE 6, Bend, OR 97701 (541) 299-2008

Ablis MCT Oil - 8floz

Lab ID: B260218-03

Ablis CBD

Harvest / Process Lot: 2026.02.11_MCT.019

METRC Batch ID: 2026.02.11_MCT.019

Date Sampled: 02/17/26

Date Printed: 02/27/26

Potency Analysis

Analytical Method: De Backer, Journal of Chromatography b.2009. 11.004 -
BBLB SOP 009 - Cannabinoids via High Performance Liquid Chromatography

Cannabinoids	mg/g	LOQ	Notes
THCA	< LOQ	0.0252	
delta 9-THC	< LOQ	0.0252	
delta 8-THC	< LOQ	0.0252	
CBDA	< LOQ	0.0252	
CBD	2.46	0.0252	
CBGA	< LOQ	0.0252	
CBG	< LOQ	0.0252	
CBN	< LOQ	0.0252	
CBC	< LOQ	0.0252	
THCV	< LOQ	0.0252	
Total CBG	< LOQ	0.0126	
Total Cannabinoids	2.46	0.0126	

Total THC
< LOQ mg/g

Total CBD
2.46 mg/g

Results that fail state testing requirements will be highlighted **Red**.


<LOQ - Results below the Limit of Quantitation

ORELAP accredited cannabinoid analytes include only CBDA, CBD, THCA, delta-9-THC, and delta-8-THC.

Acid form of THC/CBD are decarboxylated by heat, lose 12% of original mass as CO₂. Result = *bioactive*

"Total" Cannabinoid accounts for decarboxylation and moisture content. Total THC = [(THCA×0.877) + Δ9THC] / (100%-MC)

Zoe Wiggers
Technical Director



Analytical Test Report

Science First. ORELAP ID: 4101 OLCC#: 010-10233216933
20756 High Desert Court STE 6, Bend, OR 97701 (541) 299-2008

Ablis MCT Oil - 8floz

Ablis CBD

Laboratory ID: B260218-03

Quality Control Potency

Batch: B26B235 - BB Potency

Blank(B26B235-BLK1)

Analyte	Result	LOQ	Units	%Recovery Limits	Extracted	Analyzed	Notes
THCA	< LOQ	0.0240	mg/g		02/25/26 15:40	02/27/26 15:59	
delta 9-THC	< LOQ	0.0240	mg/g		02/25/26 15:40	02/27/26 15:59	
CBGA	< LOQ	0.0240	mg/g		02/25/26 15:40	02/27/26 15:59	
CBDA	< LOQ	0.0240	mg/g		02/25/26 15:40	02/27/26 15:59	
CBD	< LOQ	0.0240	mg/g		02/25/26 15:40	02/27/26 15:59	
CBN	< LOQ	0.0240	mg/g		02/25/26 15:40	02/27/26 15:59	
CBG	< LOQ	0.0240	mg/g		02/25/26 15:40	02/27/26 15:59	
delta 8-THC	< LOQ	0.0240	mg/g		02/25/26 15:40	02/27/26 15:59	
CBC	< LOQ	0.0240	mg/g		02/25/26 15:40	02/27/26 15:59	
THCV	< LOQ	0.0240	mg/g		02/25/26 15:40	02/27/26 15:59	

LCS(B26B235-BS1)

Analyte	% Recovery	LOQ	Units	%Recovery Limits	Extracted	Analyzed	Notes
THCA	104	0.0243	mg/g	90-110	02/25/26 15:40	02/27/26 15:59	
delta 9-THC	104	0.0243	mg/g	90-110	02/25/26 15:40	02/27/26 15:59	
CBDA	104	0.0243	mg/g	90-110	02/25/26 15:40	02/27/26 15:59	
CBD	106	0.0243	mg/g	90-110	02/25/26 15:40	02/27/26 15:59	
delta 8-THC	105	0.0243	mg/g	90-110	02/25/26 15:40	02/27/26 15:59	

 **Zoe Wiggers**
Technical Director



Analytical Test Report

Science First. ORELAP ID: 4101 OLCC#: 010-10233216933
20756 High Desert Court STE 6, Bend, OR 97701 (541) 299-2008

Ablis MCT Oil - 8floz

Ablis CBD

Laboratory ID: B260218-03

Notes and Definitions

- B Analyte detected in method blank, but not associated samples.
 - B2 Analyte detected in sample and associate method blank.
 - C Interference due to co-elution.
 - D Initial result exceeded calibration range, reported data are based on analysis of a dilution.
 - H Non-homogenous sample matrix affecting RPD and/or QC.
 - I Manual Integration was performed.
 - L Duplicate sample relative percent difference (RPD) exceeds QC limits.
 - M Anomalous results due to matrix interference
 - P Peaks manually split.
 - Q1 QC out of limits but still ok
 - Q2 Quality Control outside QC limits. Data considered estimate.
 - Q3 CCV/LCS was above the acceptance criteria. Non-detect samples are considered acceptable.
 - Q4 CCV/LCS was below the acceptance criteria, however the sample still exceeds the regulatory limit.
 - R Marginal Exceedence.
 - U Reported result is an estimate. The analyte was detected above the calibration range.
 - X Problems with initial analysis, reported data are from reinjection of prepared sample.
- <LOQ - Results below the Limit of Quantitation - Compound not detected

 **Zoe Wiggers**
Technical Director

Sample tested in compliance with OAR 333-007 (TNI standards). Test results meet all requirements of NELAP and the BriteBox Labs quality assurance plan unless otherwise noted. Samplings performed by BBL personnel follow sampling SOP 026. Samples not collected by BBL personnel are analyzed in "as received" condition. These results relate only to the sample included on this report. The report may not be reproduced except in full, without the written permission of BriteBox Labs Inc. Unless otherwise indicated, all analytes included on this report are accredited by ORELAP.